The link between gross profitability and pharmaceutical R&D spending

被引：97

|

作者：

Scherer, FM ^{[1
]}

机构：

[1] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA

[2] Princeton Univ, Princeton, NJ 08544 USA

来源：

HEALTH AFFAIRS | 2001年 / 20卷 / 05期

关键词：

D O I：

10.1377/hlthaff.20.5.216

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

[No abstract available]

引用

收藏

页码：216 / 220

页数：5

相关论文

共 50 条

[1] Probing the link between gross profitability and R&D spending
Lichtenberg, FR
HEALTH AFFAIRS, 2001, 20 (05) : 221 - 222
[2] On the connection between R&D, selling expenditures, and profitability in the pharmaceutical industry revisited
Koku, Paul
JOURNAL OF STRATEGIC MARKETING, 2011, 19 (03) : 273 - 283
[3] Pharmaceutical R&D spending expands at record pace
Osborne, J
R&D MAGAZINE, 1999, 41 (10): : 14UK - 16UK
[4] Measuring US Pharmaceutical Industry R&D Spending
Golec, Joseph
Vernon, John
PHARMACOECONOMICS, 2008, 26 (12) : 1005 - 1017
[5] Pharmaceutical R&D Spending and Threats of Price Regulation
Golec, Joseph
Hegde, Shantaram
Vernon, John A.
JOURNAL OF FINANCIAL AND QUANTITATIVE ANALYSIS, 2010, 45 (01) : 239 - 264
[6] Measuring US Pharmaceutical Industry R&D Spending
Joseph Golec
John Vernon
PharmacoEconomics, 2008, 26 : 1005 - 1017
[7] Patent protection and pharmaceutical R&D spending in Canada
Pazderka, B
CANADIAN PUBLIC POLICY-ANALYSE DE POLITIQUES, 1999, 25 (01): : 29 - 46
[8] Examining the link between price regulation and pharmaceutical R&D investment
Vernon, JA
HEALTH ECONOMICS, 2005, 14 (01) : 1 - 16
[9] R&D INVESTMENTS, INTANGIBLE CAPITAL AND PROFITABILITY IN THE PHARMACEUTICAL INDUSTRY
Goncharov, I
Mahlich, J. C.
Yurtoglu, B.
VALUE IN HEALTH, 2014, 17 (07) : A419 - A419
[10] Trends in pharmaceutical company R&D spending: 2005–2015
Richa Dixit
Frank S. David
Nature Reviews Drug Discovery, 2017, 16 : 376 - 376

← 1 2 3 4 5 →